Literature DB >> 29556963

Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma-An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin.

Rebecca D Chernock1,2, Eric J Duncavage3.   

Abstract

Salivary neuroendocrine carcinomas are rare and the overwhelming majority is high-grade. The parotid gland is the most commonly involved site followed by the submandibular gland. Most arise de novo but rare examples occurring as a high-grade transformation of another type of salivary gland neoplasm exist. There is significant morphologic and immunophenotypic overlap with neuroendocrine carcinomas of other sites, especially the skin. Like cutaneous neuroendocrine (or Merkel cell) carcinomas, approximately three-fourths are cytokeratin 20 positive. Cytokeratin 20 positive salivary neuroendocrine carcinomas are often referred to as being of the 'Merkel cell type' since most other non-cutaneous neuroendocrine carcinomas are cytokeratin 20 negative. Salivary neuroendocrine carcinomas may be challenging to separate from Merkel cell carcinomas of the head and neck on pathologic grounds because the latter often metastasize to the parotid gland. Clinical history is often relied upon to separate primary salivary tumors from cutaneous metastases but may not be helpful in all cases. Here we review the clinical, pathologic and molecular features of salivary neuroendocrine carcinomas focusing on high-grade major salivary gland tumors. The difficulty in separating salivary tumors from metastatic Merkel cell carcinoma will be highlighted.

Entities:  

Keywords:  Large cell neuroendocrine carcinoma; Merkel cell carcinoma; Merkel cell polyomavirus; Neuroendocrine carcinoma; Salivary; Small cell carcinoma

Mesh:

Year:  2018        PMID: 29556963      PMCID: PMC5873497          DOI: 10.1007/s12105-018-0896-4

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  49 in total

1.  Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites.

Authors:  J K Chan; S Suster; B M Wenig; W Y Tsang; J B Chan; A L Lau
Journal:  Am J Surg Pathol       Date:  1997-02       Impact factor: 6.394

2.  Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer.

Authors:  Ji Hyun Lee; Kyung Woo Kang; Hyoun Wook Lee
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Carcinosarcoma of the parotid gland: an unusual case with large-cell neuroendocrine carcinoma and rhabdomyosarcoma.

Authors:  T Ueo; N Kaku; K Kashima; T Daa; Y Kondo; K Yoshida; M Suzuki; S Yokoyama
Journal:  APMIS       Date:  2005-06       Impact factor: 3.205

4.  Small cell carcinoma in the parotid harboring Merkel cell polyomavirus.

Authors:  Clayton A Fisher; Paul W Harms; Jonathan B McHugh; Paul C Edwards; Javed Siddiqui; Nallasivam Palanisamy; Christopher K Bichakjian; Erika Benavides; Theodora E Danciu
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2014-09-17

5.  Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas.

Authors:  W Cheuk; M Y Kwan; S Suster; J K Chan
Journal:  Arch Pathol Lab Med       Date:  2001-02       Impact factor: 5.534

6.  Clonal integration of a polyomavirus in human Merkel cell carcinoma.

Authors:  Huichen Feng; Masahiro Shuda; Yuan Chang; Patrick S Moore
Journal:  Science       Date:  2008-01-17       Impact factor: 47.728

Review 7.  Metastatic Cancer to the Parotid.

Authors:  Jonathan Clark; Steven Wang
Journal:  Adv Otorhinolaryngol       Date:  2016-04-12

8.  Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.

Authors:  Madhusmita Behera; Camille Ragin; Sungjin Kim; Rathi N Pillai; Zhengjia Chen; Conor E Steuer; Nabil F Saba; Chandra P Belani; Fadlo R Khuri; Suresh S Ramalingam; Taofeek K Owonikoko
Journal:  Cancer       Date:  2015-10-06       Impact factor: 6.860

9.  Primary neuroendocrine small cell carcinoma of the parotid gland: A case report and review of the literature.

Authors:  Minda Liu; Ming Zhong; Changfu Sun
Journal:  Oncol Lett       Date:  2014-06-17       Impact factor: 2.967

10.  Large cell neuroendocrine carcinoma presenting with neck swelling in the submandibular gland: a case report.

Authors:  Hideto Kawaratani; Tatsuhiro Tsujimoto; Masaaki Yoshikawa; Fumi Kawanami; Yusaku Shirai; Hitoshi Yoshiji; Kousaku Morita; Hiroshi Fukui
Journal:  J Med Case Rep       Date:  2013-03-19
View more
  5 in total

1.  Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature.

Authors:  Sympascho Young; Justin Oh; Hussam Bukhari; Tony Ng; Nichole Chau; Eric Tran
Journal:  Head Neck Pathol       Date:  2020-04-29

2.  Adamantinoma-like Ewing Sarcoma of the Salivary Glands: A Newly Recognized Mimicker of Basaloid Salivary Carcinomas.

Authors:  Lisa M Rooper; Vickie Y Jo; Cristina R Antonescu; Vania Nose; William H Westra; Raja R Seethala; Justin A Bishop
Journal:  Am J Surg Pathol       Date:  2019-02       Impact factor: 6.394

3.  Primary Large Cell Neuroendocrine Carcinoma of the Parotid Gland. Report of a Rare Case.

Authors:  Konstantinos I Tosios; Vasileios Papanikolaou; Dimitrios Vlachodimitropoulos; Nikolaos Goutas
Journal:  Head Neck Pathol       Date:  2021-02-05

4.  Nomograms Forecasting Long-Term Overall and Cancer Specific Survival of Patients With Head and Neck Neuroendocrine Carcinoma.

Authors:  Ouying Yan; Wenji Xie; Haibo Teng; Shengnan Fu; Yanzhu Chen; Feng Liu
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 6.244

5.  Parotid metastases from primary lung cancer: Case series and systematic review of the features.

Authors:  Rulan Wang; Ting Wang; Qinghua Zhou
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.